Recently, the inhibition of the glycolate oxidase (GO) enzyme, encoded by the HAO1 gene and responsible for the synthesis of glyoxylate, has been proven to be an efficacious and safe therapy for severe PH1 patients (Martin-Higueras et al, 2016). The gene discussed is HAO1; the disease is primary hyperoxaluria type 1.